首页|University of Mons Reports Findings in Laryngeal Cancer (Surgical, Functional, a nd oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic lar yngeal Cancers: A systematic review)
University of Mons Reports Findings in Laryngeal Cancer (Surgical, Functional, a nd oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic lar yngeal Cancers: A systematic review)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Oncology - Laryngeal C ancer is the subject of a report. According to news reporting out of Mons, Belgi um, by NewsRx editors, the research stated, “This systematic review investigated the surgical, functional, and oncological outcomes of transoral robotic supragl ottic laryngectomy (TORS-SGL) for cT1-T3 laryngeal squamous cell carcinoma (LSCC ). Two investigators conducted an updated PubMed, Scopus, and Cochrane Library s ystematic review for studies investigating the surgical, functional, and oncolog ical outcomes of TORS-SGL using the PRISMA statements.” Our news journalists obtained a quote from the research from the University of M ons, “The bias analysis was conducted with the MINORS. Twenty-one studies were i ncluded, accounting for 896 patients. TORS-SGL was primarily performed for cT1 ( 39.1 %), cT2 (46.9 %), and some selected cT3 (7.7 % ) LSCCs. Surgical margins were positive in 10.8 % of cases. The me an hospital stay was 8.6 days. Hemorrhage (6.3 %), pneumonia (5.5 % ), and aspiration (1.7 %) are the primary complications. The surgic al margins were positive in 10.6 % of cases. Feeding tubes, tempor ary tracheotomy, and definitive percutaneous gastrostomy are found in 65.6 % , 19.7 %, and 5.2 % of patients, respectively. The or al diet is restarted after a mean of 7.2 days. The 5-year OS and DFS of TORS-SGL were estimated to be 78.3 %, and 91.7 %, with 5-year local-relapse-free survival and nodal-relapse-free survival of 90.8 % , and 86.6 %, respectively. The TORS-SGL is a safe, and effective s urgical approach for cT1-T3 SGL. The functional and surgical outcomes appear com parable with TOLM-SGL.”
MonsBelgiumEuropeCancerEmerging TechnologiesHealth and MedicineLaryngeal CancerLaryngeal NeoplasmsMachin e LearningOncologyRoboticsRobotsSurgery
NETL
NSTL
